Pathological findings in a patient with Fabry disease who died after 2.5 years of enzyme replacement

被引:71
|
作者
Schiffmann, R
Rapkiewicz, A
Abu-Asab, M
Ries, M
Askari, H
Tsokos, M
Quezado, M
机构
[1] NINDS, Dev & Metab Neurol Branch, NIH, Bethesda, MD 20892 USA
[2] NCI, Pathol Lab, NIH, Bethesda, MD 20892 USA
关键词
Fabry disease; lysosomes; atherosclerosis; myocardial infarction; enzyme replacement therapy; glycolipids;
D O I
10.1007/s00428-005-0089-x
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
We describe the postmortem findings of a 47-year-old man with Fabry disease, an X-linked glycolipid storage disorder, who was on enzyme replacement therapy with recombinant alpha-galactosidase A for more than 2 years. The patient had widespread atherosclerotic coronary artery disease that culminated in a massive acute myocardial infarction. Atherosclerotic lesions were seen in the right and left coronary systems, aorta, and the basilar artery. Typical Fabry cardiomyopathy and glomerular nephropathy were found. With the exception of vascular endothelial cells, extensive glycolipid storage deposits were seen in all vascular and nonvascular cells and organ systems. We conclude that, at least in this patient, repeated infusions with alpha-galactosidase A over a prolonged period did not appreciably clear storage material in cells other than vascular endothelial cells. These findings also illustrate accelerated atherosclerosis in susceptible patients with Fabry disease.
引用
收藏
页码:337 / 343
页数:7
相关论文
共 50 条
  • [11] Enzyme replacement therapy in an adolescent with Fabry disease
    Sabine Illsinger
    Thomas Luecke
    Hendrik Langen
    Anibh M. Das
    European Journal of Pediatrics, 2003, 162 : 522 - 523
  • [12] Utility of enzyme replacement therapy in Fabry disease
    Manuel Politei, Juan
    Dubroysky, Alberto
    MEDICINA CLINICA, 2010, 134 (09): : 402 - 405
  • [13] Ascending aortic remodelling in Fabry disease after long-term enzyme replacement therapy
    Pierre, Monney
    Salah, Qanadli D.
    Steven, Hajdu D.
    Christel, Tran
    Juerg, Schwitter
    Olivier, Dormond
    Frederic, Barbey
    SWISS MEDICAL WEEKLY, 2017, 147
  • [14] Fabry nephropathy before and after enzyme replacement therapy: important role of renal biopsy in patients with Fabry disease
    Kim, Il Young
    Lee, Hyun Jung
    Cheon, Chong Kun
    KIDNEY RESEARCH AND CLINICAL PRACTICE, 2021, 40 (04) : 611 - 619
  • [15] Enzyme replacement therapy in a patient of heterozygous Fabry disease: clinical and pathological evaluations by repeat kidney biopsy and a successful pregnancy
    Yoichi Iwafuchi
    Hiroki Maruyama
    Tetsuo Morioka
    Seiko Noda
    Hiroshi Nagata
    Yuko Oyama
    Ichiei Narita
    CEN Case Reports, 2017, 6 (2) : 210 - 214
  • [16] Clinical benefit of enzyme replacement therapy in Fabry disease
    Breunig, F
    Weidemann, F
    Strotmann, J
    Knoll, A
    Wanner, C
    KIDNEY INTERNATIONAL, 2006, 69 (07) : 1216 - 1221
  • [17] Enzyme replacement therapy for Fabry disease, an inherited nephropathy
    Desnick, RJ
    Banikazemi, M
    Wasserstein, M
    CLINICAL NEPHROLOGY, 2002, 57 (01) : 1 - 8
  • [18] Fabry disease in children and the effects of enzyme replacement treatment
    Guillem Pintos-Morell
    Michael Beck
    European Journal of Pediatrics, 2009, 168 : 1355 - 1363
  • [19] ENZYME REPLACEMENT THERAPY IN FABRY DISEASE: THE IMPORTANCE OF DOSE
    Manuel Politei, Juan
    Schenone, Andrea B.
    Durand, Consuelo
    Ortiz, Alberto
    REVISTA DE NEFROLOGIA DIALISIS Y TRASPLANTE, 2015, 35 (04): : 220 - 228
  • [20] Fabry disease in children and the effects of enzyme replacement treatment
    Pintos-Morell, Guillem
    Beck, Michael
    EUROPEAN JOURNAL OF PEDIATRICS, 2009, 168 (11) : 1355 - 1363